

2024 Area of Interest for CMV

CMV Areas of Interest

Effective December 2023, the CMV Investigator Studies Program (MISP) Committee will accept proposals within our current Areas of Interest (Aols) up to Apr 9, 2024. This is a competitive process that will be conducted by the CMV MISP in 2024. Decisions will be made based on scientific merit and strategic fit within the Aols. Please review the critical activities and abide by the timelines as outlined below. The program requests that investigators specify how they will support diversity in enrollment to include traditionally underrepresented minorities/ethnic groups.

- Studies that characterize the relationship between induction and/or maintenance immunosuppression strategies in Solid Organ Transplants and the burden of CMV infection/disease with an emphasis on the potential benefits of letermovir CMV prophylaxis.
 - Studies to focus on populations not well represented in Phase 3 kidney transplant trial and could include but are not limited to: patients receiving belatecept, patients treated for acute graft rejection, and durations of prophylaxis in these clinical scenarios
- Clinical studies that identify/examine new populations that might benefit from prophylaxis with letermovir beyond R+ HSCT and Kidney Transplant
 - Studies could include clinical and economic outcomes associated with CMV infection and/or disease
 - Example populations but not limited to: pediatric patients (D+/R- HSCT), liver transplant patients, Non-HSCT lymphoma patients, bispecific patients, etc.
- Studies that capture Real World Experience with letermovir in Kidney Transplant demonstrating improvements to current SOC. Studies to focus on data not reported in phase 3 Kidney Transplant clinical trial
 - Example but not limited to ability to maintain goal immunosuppression